Danaher Co. (NYSE:DHR) Stock Position Trimmed by Mutual Advisors LLC

Mutual Advisors LLC cut its position in Danaher Co. (NYSE:DHR) by 2.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,288 shares of the conglomerate’s stock after selling 190 shares during the quarter. Mutual Advisors LLC’s holdings in Danaher were worth $1,521,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of DHR. Decker Retirement Planning Inc. bought a new stake in Danaher in the 4th quarter valued at about $31,000. Teachers Insurance & Annuity Association of America bought a new stake in Danaher in the 3rd quarter valued at about $39,000. MidAtlantic Capital Management Inc. bought a new stake in Danaher in the 3rd quarter valued at about $40,000. FSA Wealth Management LLC bought a new stake in Danaher in the 3rd quarter valued at about $50,000. Finally, Darwin Wealth Management LLC bought a new stake in Danaher in the 3rd quarter valued at about $55,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

DHR stock opened at $245.95 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The stock has a market cap of $177.65 billion, a P/E ratio of 46.94, a P/E/G ratio of 4.43 and a beta of 0.83. The firm has a 50 day simple moving average of $235.02 and a 200 day simple moving average of $253.41. Danaher Co. has a 52 week low of $225.42 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same period last year, the company posted $2.02 earnings per share. Research analysts anticipate that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio is currently 20.61%.

Analyst Ratings Changes

Several research firms have commented on DHR. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a research note on Thursday, October 31st. Citigroup lowered their target price on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Evercore ISI raised their target price on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Stephens reissued an “overweight” rating and set a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. Finally, Scotiabank began coverage on shares of Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price on the stock. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $285.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.